Tetradentate Copper Chelators for Selective Cancer Cell Targeting
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current chemotherapy drugs lack specificity and safety, leading to ineffective treatment of cancer due to non-selective metal ion interaction and potential toxicity, despite the role of metal ions in cancer cell metabolism and angiogenesis.
Innovation Solution
Development of highly selective copper chelators, specifically TDMQ20, which targets cancer cells by inducing ROS production, mitochondrial damage, and apoptosis, while maintaining lower toxicity to non-cancer cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional chemotherapy drugs are used, then cancer treatment is provided, but lack of specificity and high toxicity to non-cancer cells occurs
Solution Approach 1:
The patent applies local quality by designing copper chelators with specific molecular structures (tetradentate monoquinoline series) that selectively interact with copper ions in cancer cells. The chelators are tailored to target cancer cells specifically, as evidenced by the selectivity index of 2.5-2.8 for cancer cells over normal cells, thereby reducing toxicity to non-cancer cells while maintaining anti-cancer efficacy.
Solution Approach 2:
The patent employs parameter changes by modifying the chemical structure of copper chelators within the TDMQ series, optimizing binding affinity and selectivity. The systematic variation of molecular parameters in the chelator series enables fine-tuning of copper ion binding characteristics to achieve high specificity for cancer cells, as demonstrated by the improved safety window compared to conventional drugs like 5-FU.
2Reliability
If non-selective metal ion interaction is used, then cancer cell metabolism is disrupted, but lack of specificity and potential toxicity occurs
Solution Approach 1:
The patent applies local quality by designing copper chelators with specific molecular structures (tetradentate monoquinoline series) that selectively interact with copper ions in cancer cells. The chelators are tailored to target cancer cells specifically, as evidenced by the selectivity index of 2.5-2.8 for cancer cells over normal cells, thereby reducing toxicity to non-cancer cells while maintaining anti-cancer efficacy.
Solution Approach 2:
The patent uses copper ions as an intermediary target. Instead of directly attacking cancer cells with non-selective agents, the chelators first bind selectively to copper ions, which are present at elevated levels in cancer cells. This intermediary approach enables specific disruption of cancer cell metabolism through copper depletion, while avoiding non-specific toxicity to normal cells.
3Reliability
If conventional drugs like 5-FU are used, then cancer treatment is achieved, but lower safety window and higher toxicity occurs
Solution Approach 1:
The patent employs parameter changes by modifying the chemical structure of copper chelators within the TDMQ series, optimizing binding affinity and selectivity. The systematic variation of molecular parameters in the chelator series enables fine-tuning of copper ion binding characteristics to achieve high specificity for cancer cells, as demonstrated by the improved safety window compared to conventional drugs like 5-FU.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
TDMQ20 demonstrates higher cytotoxicity and selectivity for cancer cells, inhibiting proliferation and metastasis, with improved safety profiles compared to 5-FU, through dose-dependent mechanisms.
Implementation Method 1
TDMQ20 induces the production of ROS (reactive oxygen species), mitochondrial damage and cancer cell apoptosis
Implementation Method 2
TDMQ20 induces the production of ROS (reactive oxygen species), mitochondrial damage and cancer cell apoptosis
Data Source
AI summary
Copper chelators of the tetradentate monoquinoline (TDMQ) series are highly efficient against several cancer cell lines. One of these selective copper chelators, TDMQ20, is highly cytotoxic on the non-small cell lung carcinoma (A549), the cervix cancer HeLa and the hepatocarcinoma HepG2 cell cultures, with IC50 values ranging from 14 to 16 μM in vitro, lower than those obtained with the reference drug 5-fluorouracil (5-FU). TDMQ20 also exhibits a significant antiproliferative activity on HeLa cells in vitro. The mechanism of its cytotoxicity and antiproliferative activity involved intracellular production of reactive oxygen species, drastic mitochondrial damages and induction of apoptosis. The selectivity of TDMQ20 for cancer cells with respect to non-cancer human cells is higher than that of 5-FU, the reference drug. These data strongly support the selection of TDMQ20 as drug-candidate to treat several human cancers.